carmustine has been researched along with Blood Diseases in 20 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty six (17 males) patients with glioblastoma (GBL), median age 55 years, median Karnofsky Index (KI) 70/100, and 11 patients (9 males) with anaplastic astrocytoma (AA), median age 56 years, median KI 70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m2 on day 1, BCNU 150 mg/m2 on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15." | 9.08 | Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study. ( De Witte, O; Hildebrand, J; Sahmoud, T, 1998) |
| "The combination of dacarbazine (DTIC, 220 mg/m2) and cisplatin (DDP, 25 mg/m2) IV daily for 3 days every 3 weeks, carmustine (BCNU, 150 mg/m2) IV every 6 weeks, and tamoxifen (TAM, 10 mg orally twice daily) produced a 50% objective response rate in patients with metastatic melanoma." | 7.67 | The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD, 1989) |
| "Twenty six (17 males) patients with glioblastoma (GBL), median age 55 years, median Karnofsky Index (KI) 70/100, and 11 patients (9 males) with anaplastic astrocytoma (AA), median age 56 years, median KI 70/100 were treated at recurrence with dibromodulcitol (DBD) 1400 mg/m2 on day 1, BCNU 150 mg/m2 on day 2, and procarbazine (PCZ) 150 mg/day on days 1 to 15." | 5.08 | Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study. ( De Witte, O; Hildebrand, J; Sahmoud, T, 1998) |
| "Four hundred forty previously untreated patients with active multiple myeloma were entered into a randomized trial (Southwest Oncology Group [SWOG] study 7927/28) comparing vincristine, melphalan, Cytoxan (Mead Johnson & Company, Evansville, Ind), and prednisone (VMCP) alternating with vincristine, BCNU, Adriamycin (Adria Laboratories, Columbus, Ohio) and prednisone (VBAP) with or without levamisole with vincristine, Cytoxan, and prednisone (VCP) with or without levamisole for induction therapy." | 5.06 | Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. ( Bonnet, J; Carter, S; Costanzi, JJ; Dabich, L; Dixon, DO; Durie, BG; Files, JC; Rivkin, S; Salmon, SE; Stephens, R, 1986) |
| "In patients with glioblastoma multiforme (GBM), there is no consensus on the sequential use of two existing regimens: post-operative Gliadel implantation into the surgical cavity and concomitant temozolomide with radiotherapy followed by adjuvant temozolomide ('Stupp protocol')." | 4.87 | The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. ( Achawal, S; Dixit, S; Hingorani, M; Scott, I, 2011) |
| "The combination of dacarbazine (DTIC, 220 mg/m2) and cisplatin (DDP, 25 mg/m2) IV daily for 3 days every 3 weeks, carmustine (BCNU, 150 mg/m2) IV every 6 weeks, and tamoxifen (TAM, 10 mg orally twice daily) produced a 50% objective response rate in patients with metastatic melanoma." | 3.67 | The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD, 1989) |
| "Severe infections were seen as often with VBMCP as with VBMCP + rIFN(alpha2) (13% vs." | 2.69 | The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. ( Greipp, PR; Kay, NE; Keimowitz, RM; Kyle, RA; Lenhard, RE; Leong, T; Oken, MM; Van Ness, B, 1999) |
| "Twenty-one patients had malignant lymphomas, three, acute lymphoblastic leukemia (ALL), and two, malignant thymomas." | 1.27 | Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. ( Blaise, D; Gaspard, MH; Gastaut, JA; Maraninchi, D; Michel, G; Novakovitch, G; Rossi, JF; Stoppa, AM; Tubiana, N; Weiller, PJ, 1988) |
| "Of 16 evaluable patients with breast cancer, 15 responded (six complete responses)." | 1.27 | High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. ( Andersen, J; Antman, K; Eder, JP; Elias, A; Finberg, R; Henner, WD; Peters, WP; Schryber, S; Shea, T; Wilmore, D, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (65.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 2 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mikesch, JH | 1 |
| Kuhlmann, M | 1 |
| Demant, A | 1 |
| Krug, U | 1 |
| Thoennissen, GB | 1 |
| Schmidt, E | 1 |
| Kessler, T | 1 |
| Schliemann, C | 1 |
| Pohlen, M | 1 |
| Mohr, M | 1 |
| Evers, G | 1 |
| Köhler, G | 1 |
| Wessling, J | 1 |
| Mesters, R | 1 |
| Müller-Tidow, C | 1 |
| Berdel, WE | 1 |
| Thoennissen, NH | 1 |
| Dixit, S | 1 |
| Hingorani, M | 1 |
| Achawal, S | 1 |
| Scott, I | 1 |
| Brandes, AA | 1 |
| Tosoni, A | 1 |
| Amistà, P | 1 |
| Nicolardi, L | 1 |
| Grosso, D | 1 |
| Berti, F | 1 |
| Ermani, M | 1 |
| Hildebrand, J | 2 |
| Gorlia, T | 1 |
| Kros, JM | 1 |
| Afra, D | 1 |
| Frenay, M | 1 |
| Omuro, A | 1 |
| Stupp, R | 1 |
| Lacombe, D | 1 |
| Allgeier, A | 1 |
| van den Bent, MJ | 1 |
| Bakemeier, RF | 1 |
| Anderson, JR | 1 |
| Costello, W | 1 |
| Rosner, G | 1 |
| Horton, J | 1 |
| Glick, JH | 1 |
| Hines, JD | 1 |
| Berard, CW | 1 |
| DeVita, VT | 1 |
| Robustelli della Cuna, G | 1 |
| Paoletti, P | 1 |
| Bernardo, G | 1 |
| Knerich, R | 1 |
| Butti, G | 1 |
| Cuzzoni, Q | 1 |
| Phillips, GL | 1 |
| Fay, JW | 1 |
| Herzig, GP | 1 |
| Herzig, RH | 1 |
| Weiner, RS | 1 |
| Wolff, SN | 1 |
| Lazarus, HM | 1 |
| Karanes, C | 1 |
| Ross, WE | 1 |
| Kramer, BS | 1 |
| Volkin, RL | 1 |
| Shadduck, RK | 1 |
| Winkelstein, A | 1 |
| Zeigler, ZR | 1 |
| Selker, RG | 1 |
| De Witte, O | 1 |
| Sahmoud, T | 1 |
| Oken, MM | 1 |
| Leong, T | 1 |
| Lenhard, RE | 1 |
| Greipp, PR | 1 |
| Kay, NE | 1 |
| Van Ness, B | 1 |
| Keimowitz, RM | 1 |
| Kyle, RA | 1 |
| Papadakis, V | 1 |
| Dunkel, IJ | 1 |
| Cramer, LD | 1 |
| Kramer, E | 1 |
| Papadopoulos, E | 1 |
| Goldman, S | 1 |
| Packer, RJ | 1 |
| Willoughby, M | 1 |
| Baker, D | 1 |
| Garvin, J | 1 |
| Strandjord, S | 1 |
| Coccia, P | 1 |
| Kaplan, AM | 1 |
| Klemperer, M | 1 |
| Finlay, JL | 1 |
| McClay, EF | 1 |
| Mastrangelo, MJ | 1 |
| Sprandio, JD | 1 |
| Bellet, RE | 1 |
| Berd, D | 1 |
| Gaspard, MH | 1 |
| Maraninchi, D | 1 |
| Stoppa, AM | 1 |
| Gastaut, JA | 1 |
| Michel, G | 1 |
| Tubiana, N | 1 |
| Blaise, D | 1 |
| Novakovitch, G | 1 |
| Rossi, JF | 1 |
| Weiller, PJ | 1 |
| Schnitzler, G | 1 |
| Queisser, W | 1 |
| Heim, ME | 1 |
| König, H | 1 |
| Katz, R | 1 |
| Fritze, D | 1 |
| Herrmann, R | 1 |
| Arnold, H | 1 |
| Henss, H | 1 |
| Trux, FA | 1 |
| De Lisi, V | 1 |
| Cocconi, G | 1 |
| Tonato, M | 1 |
| Di Costanzo, F | 1 |
| Leonardi, F | 1 |
| Soldani, M | 1 |
| Durie, BG | 1 |
| Dixon, DO | 1 |
| Carter, S | 1 |
| Stephens, R | 1 |
| Rivkin, S | 1 |
| Bonnet, J | 1 |
| Salmon, SE | 1 |
| Dabich, L | 1 |
| Files, JC | 1 |
| Costanzi, JJ | 1 |
| Antman, K | 1 |
| Eder, JP | 1 |
| Elias, A | 1 |
| Shea, T | 1 |
| Peters, WP | 1 |
| Andersen, J | 1 |
| Schryber, S | 1 |
| Henner, WD | 1 |
| Finberg, R | 1 |
| Wilmore, D | 1 |
| Hartmann, O | 1 |
| Kalifa, C | 1 |
| Beaujean, F | 1 |
| Bayle, C | 1 |
| Benhamou, E | 1 |
| Lemerle, J | 1 |
| Durant, JR | 1 |
| Lessner, HE | 1 |
| Moertel, CG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY[NCT00002620] | Phase 3 | 212 participants (Anticipated) | Interventional | 1994-11-30 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
1 review available for carmustine and Blood Diseases
| Article | Year |
|---|---|
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2011 |
8 trials available for carmustine and Blood Diseases
| Article | Year |
|---|---|
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; C | 2004 |
Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Chemotherapy, | 2008 |
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Clinical Trials | 1984 |
Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine--a phase-II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Female; Glioblastoma; H | 1998 |
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Disea | 1999 |
Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Doxorubicin; F | 1986 |
Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D | 1986 |
Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trial | 1986 |
11 other studies available for carmustine and Blood Diseases
| Article | Year |
|---|---|
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Co | 2013 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Central Nervous S | 1983 |
Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cimetidine; Drug Synergism; Female; Glioma; Guanidines; He | 1982 |
High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 2000 |
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Hematolo | 1989 |
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1988 |
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1987 |
Treatment of advanced neuroblastoma with two consecutive high-dose chemotherapy regimens and ABMT.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; | 1985 |
Development of four-drug BCNU combination chemotherapy regimens.
Topics: Carmustine; Cyclophosphamide; Evaluation Studies as Topic; Hematologic Diseases; Hodgkin Disease; Hu | 1973 |
Therapy of advanced gastrointestinal cancer with the nitrosoureas.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow Diseases; Carmustine; Colonic Neoplasms; Cyclohex | 1973 |